Display options
Cite
Sun M, Lemaçon A, Legault MA, et al. Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. Pharmacogenomics J. 2021;21(4):446-457doi: 10.1038/s41397-021-00221-z.
Sun, M., Lemaçon, A., Legault, M. A., Asselin, G., Provost, S., Aschard, H., Barhdadi, A., Zada, Y. F., Valois, D., Mongrain, I., Tardif, J. C., & Dubé, M. P. (2021). Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. The pharmacogenomics journal, 21(4), 446-457. https://doi.org/10.1038/s41397-021-00221-z
Sun, Maxine, et al. "Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women." The pharmacogenomics journal vol. 21,4 (2021): 446-457. doi: https://doi.org/10.1038/s41397-021-00221-z
Sun M, Lemaçon A, Legault MA, Asselin G, Provost S, Aschard H, Barhdadi A, Zada YF, Valois D, Mongrain I, Tardif JC, Dubé MP. Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. Pharmacogenomics J. 2021 Aug;21(4):446-457. doi: 10.1038/s41397-021-00221-z. Epub 2021 Mar 01. PMID: 33649522.
Copy Download .nbib Format: NLM
Share it on

Pharmacogenomics J. 2021 Aug;21(4):446-457. doi: 10.1038/s41397-021-00221-z. Epub 2021 Mar 01.

Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women.

The pharmacogenomics journal

Maxine Sun, Audrey Lemaçon, Marc-André Legault, Géraldine Asselin, Sylvie Provost, Hugues Aschard, Amina Barhdadi, Yassamin Feroz Zada, Diane Valois, Ian Mongrain, Jean-Claude Tardif, Marie-Pierre Dubé

Affiliations

  1. Université de Montréal Beaulieu-Saucier Pharmacogenomics Center, Montreal, QC, Canada.
  2. Montreal Heart Institute, Montreal, QC, Canada.
  3. Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
  4. Centre de Bioinformatique, Biostatistique et Biologie Intégrative (C3BI), Institut Pasteur, Paris, France.
  5. Université de Montréal Beaulieu-Saucier Pharmacogenomics Center, Montreal, QC, Canada. [email protected].
  6. Montreal Heart Institute, Montreal, QC, Canada. [email protected].
  7. Faculty of Medicine, Université de Montréal, Montreal, QC, Canada. [email protected].

PMID: 33649522 DOI: 10.1038/s41397-021-00221-z

Abstract

We sought to perform a genomic evaluation of the risk of incident cancer in statin users, free of cancer at study entry. Patients who previously participated in two phase IV trials (TNT and IDEAL) with genetic data were used (n

© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.

References

  1. Taylor F, Huffman M, Macedo A, Moore T, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;31:CD004816. - PubMed
  2. Silverman M, Ference B, Im K, Wiviott S, Giugliano R, Grundy S, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions a systematic review and meta-analysis. JAMA. 2016;316:1289–97. - PubMed
  3. Cholesterol Treatment Trialists (CTT) Collaborators. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012;7:e29849. - PubMed
  4. Wenger N, Lewis S, Welty F, Herrington D, Bittner V.TNT Steering Committee and Investigators Beneficial effects of aggressive low-density liprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. BMJ. 2007;94:434–9. - PubMed
  5. Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T.Cholesterol and Recurrent Events Trial investigators et al.The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.N Engl J Med. 1996;335:1001–9. - PubMed
  6. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the west of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–86. - PubMed
  7. Shepherd J, Blauw G, Murphy M, Bollen E, Buckley B, Cobbe S, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30. - PubMed
  8. Blais L, Desgagné A, LeLorier J. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer. JAMA Intern Med. 2000;160:2363–8. - PubMed
  9. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. EJC. 2008;44:2122–32. - PubMed
  10. Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–92. - PubMed
  11. Tran KT, McMenamin ÚC, Coleman HG, Cardwell CR, Murchie P, Iversen L, et al. Statin use and risk of liver cancer: evidence from two population-based studies. Int J Cancer. 2020;146:1250–60. https://doi.org/10.1002/ijc.32426 . Epub 4 Jun 2019. - PubMed
  12. LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart J, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35. - PubMed
  13. Pedersen T, Faergeman O, Kastelein J, Olsson A, Tikkanen M, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45. - PubMed
  14. Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. Design and baseline characteristics of the incremental decrease in end points through aggressive lipid lowering study. Am J Cardiol. 2004;94:720–4. - PubMed
  15. Waters D, Guyton J, Herrington D, McGowan M, Wenger N, Shear C, et al. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93:154–8. - PubMed
  16. Wu Y, Byrne EM, Zheng Z, Kemper KE, Yengo L, Mallett AJ, et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat Commun. 2019;10:1891. https://doi.org/10.1038/s41467-019-09572-5 . - PubMed
  17. Lemieux-Perreault L, Legault M, Asselin G, Dubé M. Genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools. Bioinformatics. 2016;32:3661–3. - PubMed
  18. Mägi R, Morris AP. GWAMA: software for genome-wide association meta-analysis. BMC Bioinforma. 2010;11:288. - PubMed
  19. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. - PubMed
  20. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. StatMed. 2002;21:1539–58. - PubMed
  21. Cochran W. The combination of estimates from different experiements. Biometrics. 1954;10:101–29. - PubMed
  22. Nelson CP, Goel AA-O, Butterworth AS, Kanoni S, Webb TR, Marouli E, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. (1546–1718 (Electronic)). - PubMed
  23. Meijers W, Boer R. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115:844–53. - PubMed
  24. Shiina T, Hosomichi K, Inoko H, Kulski J. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54:15–39. - PubMed
  25. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype–phenotype associations. Bioinformatics. 2016;32:3207–9. - PubMed
  26. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype–phenotype associations. Bioinformatics. 2019;35:4851–3. - PubMed
  27. Couture A, Garnier A, Docagne F, Boyer O, Vivien D, Le-Mauff B, et al. HLA-Class II artificial antigen presenting cells in CD4+ T cell-based immunotherapy. Front Immunol. 2019;10:1081. - PubMed
  28. Chemin K, Gerstner C, Malmström V. Effector functions of CD4+ T cells at the site of local autoimmune inflammation-lessons from rheumatoid arthritis. Front Immunol. 2019;10:353. - PubMed
  29. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45. - PubMed
  30. Capone I, Marchetti P, Ascierto PA, Malorni W, Gabriele L. Sexual dimorphism of immune responses: a new perspective in cancer immunotherapy. Front Immunol. 2018;9:552. - PubMed
  31. van Vollenhoven RF. Sex differences in rheumatoid arthritis: more than meets the eye. BMC Med. 2009;7:12. - PubMed
  32. Nair B, Taylor-Gjevre R, Wu L, Jin S, Quail JM. Incidence and prevalence of rheumatoid arthritis in Saskatchewan, Canada: 2001-2014. BMC Rheumatol. 2019;3:28. - PubMed
  33. Frostegård J, Zhang Y, Sun J, Yan K, Liu A. Oxidized low‐density lipoprotein (OxLDL)–treated dendritic cells promote activation of T cells in human atherosclerotic plaque and blood, which is repressed by statins: microRNA let‐7c is integral to the effect. J Am Heart Assoc. 5:e003976. - PubMed
  34. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi X-B, Zou JX, et al. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS ONE. 2012;7:e32832. - PubMed
  35. Mizuno R, Kawada K, Sakai Y. The molecular basis and therapeutic potential of Let-7 MicroRNAs against colorectal cancer. Can J Gastroenterol Hepatol. 2018;2018:5769591. - PubMed
  36. Biamonte F, Santamaria G, Sacco A, Perrone FM, Di Cello A, Battaglia AM, et al. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. Sci Rep. 2019;9:5668. - PubMed
  37. Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. Cancer Lett. 2014;342:43–51. - PubMed
  38. Coussens L, Werb Z. Inflammation and cancer. Nature. 2010;420:860–7. - PubMed
  39. Rhodes DA, Trowsdale J. Genetics and molecular genetics of the MHC. Rev Immunogenet. 1999;1:21–31. - PubMed
  40. Nangalia J, Campbell PJ. Genome sequencing during a patient’s journey through cancer. N Engl J Med. 2019;381:2145–56. - PubMed
  41. Trowsdale J. Genomic structure and function in the MHC. Trends Genet. 1993;9:117–22. - PubMed
  42. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. Gene map of the extended human MHC. Nat Rev Genet. 2004;5:889–99. - PubMed
  43. Howell WM. HLA and disease: guilt by association. Int J Immunogenet. 2014;41:1–12. - PubMed
  44. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet. 2009;373:659–72. - PubMed
  45. Busch R, De Riva A, Hadjinicolaou AV, Jiang W, Hou T, Mellins ED. On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Exp Rev Mol Med. 2012;14:e15–e15. - PubMed
  46. Illing PT, Vivian JP, Purcell AW, Rossjohn J, McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol. 2013;25:81–89. - PubMed
  47. Kennedy AE, Ozbek U, Dorak MT. What has GWAS done for HLA and disease associations? Int J Immunogenet. 2017;44:195–211. - PubMed
  48. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95. - PubMed
  49. Schreiber R, Old L, Smyth M. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70. - PubMed

Publication Types

Grant support